This document is NOT medical advice. GCA is a medical emergency. Untreated GCA causes permanent blindness within hours to days of visual symptoms. High-dose corticosteroids MUST be initiated immediately upon clinical suspicion — before biopsy results. Do NOT delay steroid treatment for any reason, including to start this protocol. The Christos™ protocol is adjunctive to — never a replacement for — standard corticosteroid therapy. © 2026 Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Table of Contents
Overview and Novel Cross-Disease Connection
Giant cell arteritis (GCA) is the most common primary systemic vasculitis in adults over 50. It causes permanent vision loss in 15-20% of untreated patients within weeks of visual symptom onset — through anterior ischemic optic neuropathy (AION) or central retinal artery occlusion. High-dose corticosteroids prevent blindness but cause severe long-term toxicity: osteoporosis (30-50%), new-onset diabetes (15-25%), hypertension (30-40%), cataracts, serious infections, and adrenal suppression. Flare rates remain 50-60% on standard prednisone. Tocilizumab (FDA-approved 2017, GiACTA trial — Stone et al. NEJM 2017) achieves steroid-free remission in 56% but costs $15,000-20,000/year.
The Christos™ framework proposes GCA is a vascular coherence collapse disorder — when endothelial coherence (C_vascular) falls below a critical threshold (estimated ≤ 0.35-0.40 in active GCA), three systems fail: vessel wall immune tolerance, endothelial integrity, and systemic vascular coherence. The protocol targets all three through 14 modalities with steroid-sparing as the primary strategic goal — reducing the required prednisone dose, accelerating the taper, preventing flares, and protecting against long-term steroid toxicity. Thirteen falsifiable predictions are provided. Proprietary fluid and device specifications available under NDA.
The GCA Emergency — Why Conventional Medicine Falls Short
1.1 Clinical Landscape
| Parameter | Value |
|---|---|
| Prevalence | 200/100,000 persons over age 50 in Northern European populations; peak incidence 70-80 years; female:male 3:1 |
| Vision loss risk | 15-20% untreated; occurs within days to weeks of first visual symptoms |
| Reversibility of vision loss | NONE — once lost, visual function does not return with any current treatment |
| Flare rate on standard prednisone | 50-60% within 2 years; requires restarting high-dose steroids |
| Aortic aneurysm risk | 17× elevated vs. age-matched controls; develops silently years after diagnosis |
| Tocilizumab (GiACTA 2017) | 56% sustained remission without steroids at 52 weeks; FDA-approved; $15,000-20,000/year |
1.2 The Steroid Toxicity Problem — Why Steroid-Sparing Is the Primary Goal
| Side Effect | Prevalence in GCA | Clinical Consequence |
|---|---|---|
| Osteoporosis / vertebral fracture | 30-50% | Spinal fractures; height loss; chronic pain; nursing home placement |
| New-onset diabetes mellitus | 15-25% | Lifelong metabolic disease added to existing condition |
| Hypertension | 30-40% | Additional cardiovascular risk in already high-risk elderly population |
| Cataracts | 30-50% with long-term use | Surgery required — treating vision loss causes cataract risk |
| Serious infections | 2-3× elevated risk | Pneumonia, sepsis in elderly; significant mortality |
| Adrenal suppression | Near-universal > 3-6 months | Adrenal crisis risk; illness-related cortisol surge failure |
| Muscle weakness / myopathy | 20-30% | Falls risk in elderly; functional decline |
Every week of lower prednisone dose or faster taper is clinically significant for the elderly GCA patient. This is the primary strategic goal of the entire Christos™ GCA protocol.
The Coherence Model of Giant Cell Arteritis
2.1 Triad of Vascular Coherence Collapse
| System | Coherent State | GCA Collapse State | C at Failure |
|---|---|---|---|
| Vascular endothelium | Tight junctions intact; eNOS active; NO production; immune tolerance signals to vessel-patrolling T cells | ICAM-1/VCAM-1 upregulation; dendritic cell recruitment; loss of immune tolerance signal to vessel wall | ≤ 0.35 |
| Vessel wall immune tolerance | CD4+ T cells calibrated to recognize vessel wall as self; adventitial DCs in tolerance state | Th1/Th17 polarization; granuloma formation; giant cell aggregation around internal elastic lamina | ≤ 0.40 |
| Systemic vascular coherence | Consistent field signature across all vessels; immune surveillance calibrated to vessel architecture | Systemic spread to aorta, subclavian, axillary, iliac arteries through connected vascular tree | ≤ 0.45 |
2.2 The IL-6 Axis — Primary Inflammatory Driver
| IL-6 Component | Role in GCA | Protocol Target |
|---|---|---|
| IL-6 (macrophage/stromal) | Primary systemic driver; drives CRP/ESR elevation; amplifies Th17; causes fever and constitutional symptoms | Tocilizumab/sarilumab; curcumin (NF-κB); omega-3; 396 Hz coherence field (immune reset) |
| IL-17 (Th17 cells) | Vascular neutrophil recruitment; inflammation amplification; mediates some steroid-resistant disease | LDN (Th17 suppression); vitamin D; resveratrol (Sirt1) |
| IFN-gamma (Th1 cells) | Activates macrophages; drives giant cell formation; central to granuloma maintenance | LDN (immune rebalancing); PEMF (anti-inflammatory) |
| TGF-β1 (granuloma-associated) | Drives intimal hyperplasia and vessel wall fibrosis — same Smad2/3 pathway as scleroderma | 528 Hz PBM (Chen 2019; Wang 2018/2020 — identical mechanism to anti-fibrotic in CKD and scleroderma) |
Standard of Care — Non-Negotiable
VISION SYMPTOMS IN GCA ARE A MEDICAL EMERGENCY. Any visual disturbance (amaurosis fugax, diplopia, visual field loss, sudden vision loss) requires: (1) High-dose IV methylprednisolone 500-1000 mg/day ×3 days or oral prednisone 1 mg/kg/day IMMEDIATELY; (2) Emergency ophthalmology and rheumatology SAME DAY; (3) Temporal artery biopsy within 2 weeks. The Christos™ protocol begins simultaneously — never instead of, never before these steps.
3.1 Standard Therapy + Coherence Adjunct by Clinical Scenario
| Clinical Situation | Standard Treatment | Coherence Protocol Phase 0 |
|---|---|---|
| Suspected GCA — no vision symptoms | Prednisone 40-60 mg/day; biopsy within 2 weeks | Start VasculiFlux 30 mL 2× daily; vitamin D3 10,000 IU; NAC 1200 mg; omega-3 3g; modified coherence lock 3× daily |
| GCA with vision symptoms (AION/CRAO) | IV methylprednisolone 500-1000 mg/day ×3 STAT; then prednisone 1 mg/kg/day; ophthalmology same day | Same as above + aspirin 81 mg/day + PBM periorbital (NOT into eyes — opaque goggles mandatory) within 24-48 hr |
| Large vessel involvement (aortic) | Prednisone 40-60 mg; PET-CT or MRI-A imaging; cardiology/vascular co-management | Add thoracic Vascular Resonator; HBOT when clinically stable |
| PMR only (no cranial GCA) | Prednisone 12.5-25 mg/day (lower dose) | Full coherence protocol — highest steroid-sparing opportunity of all GCA presentations |
3.2 Steroid-Sparing Taper Strategy
| Taper Phase | Standard Timeline | Coherence-Assisted Target | Protocol Elements Enabling Faster Taper |
|---|---|---|---|
| High-dose (40-60 mg) | Weeks 1-4 | Weeks 1-4 (same — do not rush) | VasculiFlux; vitamin D; NAC; coherence lock; begin LDN 1.5 mg |
| Rapid reduction (40→20 mg) | Months 1-3 | Months 1-2.5 | LDN titrating to 3.0-4.5 mg; PBM begins; PEMF begins; tocilizumab if available |
| Slow reduction (20→10 mg) | Months 3-9 | Months 2.5-6 | HBOT begins; Vascular Resonator 24/7; ESR/CRP/IL-6 monthly monitoring |
| Minimal dose (10→5 mg) | Months 9-18 | Months 6-12 | LDN at optimal dose; full 14-modality protocol maintaining vascular coherence |
| Discontinuation | Months 18-36+ | Months 12-24 | All coherence modalities continue; monitor 12 months post-taper |
CAUTION: Taper only when asymptomatic AND ESR < 30 mm/hr AND CRP < 0.5 mg/dL. Never taper faster than disease activity allows regardless of protocol progress.
The Four-Phase GCA Coherence Protocol
4.1 14-Modality Protocol Matrix
| # | Modality | Phase 0 | Phase 1 (Wks 1-12) | Phase 2 (Wks 13-24) | Phase 3 (Wks 25-52) | Phase 4 (Wk 53+) |
|---|---|---|---|---|---|---|
| 1 | Corticosteroids | IMMEDIATELY | Taper per response | Continue taper | Low-dose or stop | Discontinue if possible |
| 2 | Tocilizumab/sarilumab | If vision symptoms | 162 mg SC weekly | Continue | Continue | Per rheumatologist |
| 3 | LDN | — | 1.5→4.5 mg nightly | 3.0-4.5 mg nightly | Maintain | Continue indefinitely |
| 4 | Vitamin D3 | 10,000 IU immediately | 10,000 IU + K2 200 mcg | 10,000 IU | 5,000 IU | 5,000 IU |
| 5 | NAC | 1200 mg immediately | 1200-2400 mg/day | 1200-2400 mg/day | 1200 mg/day | 1200 mg/day |
| 6 | Curcumin BCM-95 | 2 g/day immediately | 2-4 g/day | 2-4 g/day | 1-2 g/day | 1-2 g/day |
| 7 | Omega-3 EPA/DHA | 3 g/day immediately | 3-5 g/day | 3-5 g/day | 3 g/day | 3 g/day |
| 8 | PBM 660+850 nm | — | Begin wk 2-4; 5× weekly | 5× weekly | 3-5× weekly | 3× weekly |
| 9 | PEMF 7.83+528 Hz | — | Begin wk 2; 2× daily | 2× daily | 1× daily | 1× daily |
| 10 | HBOT 2.0 ATA | — | Begin wk 4-6; 3-5× weekly | 3-5× weekly | 2× weekly | 1× weekly |
| 11 | Christos™ VasculiFlux | 30 mL 2× daily | 30 mL 3× daily | 30 mL 3× daily | 30 mL 2× daily | 30 mL 2× daily |
| 12 | Vascular Resonator | — | Begin wk 2; 24/7 | 24/7 | Overnight | 3-4 nights/week |
| 13 | Modified coherence lock | 3× daily immediately | 3× daily | 3× daily | 2× daily | 1-2× daily |
| 14 | Steroid side-effect protection | Immediately | Full protocol | Full protocol | Reduce as steroids taper | Maintain bone/glucose protection |
4.2 Coherence Chamber Session — Vascular Solfeggio Protocol
4.3 Steroid Side Effect Protection — Non-Negotiable Adjuncts
| Side Effect Protected Against | Intervention | Evidence |
|---|---|---|
| Osteoporosis (30-50% of GCA patients) | Calcium 1200 mg + D3 10,000 IU (already in protocol) + K2 MK-7 200 mcg; bisphosphonate per rheumatologist; PEMF bone protocol | ACR glucocorticoid-induced osteoporosis guidelines 2017; multiple bisphosphonate RCTs |
| Steroid-induced diabetes | Low-carb diet < 100g carbs/day; berberine 1000 mg/day; blood glucose monitoring | Berberine — Yin 2008, AMPK activation equivalent to metformin |
| Hypertension | Magnesium taurate 1 g/day; omega-3; sodium reduction; BP monitoring | Shechter 2000 — Mg reduces vascular resistance |
| Muscle wasting/falls risk | Protein 1.2-1.5 g/kg/day; creatine 3-5 g/day; PT 3× weekly | Chilibeck 2017 — creatine preserves muscle mass on steroids |
Christos™ Fluid and Device Platform — Overview
Complete formulations, device crystal array configurations, frequency parameters, and manufacturing specifications are proprietary and available under NDA. Contact christosenergy.com for licensing inquiries.
5.1 Christos™ VasculiFlux — Oral Coherence Fluid
VasculiFlux addresses three GCA therapeutic targets: vascular anti-inflammation (suppressing IL-6, TNF-α, IFN-γ, IL-17); steroid-sparing (reducing inflammatory signals requiring high steroid doses); and endothelial restoration (restoring eNOS function, NO production, tight junction integrity). Base: Christos™ UHF structured deuterium-depleted water with 24-hour Solfeggio frequency imprinting (528 Hz primary, 8-hour window).
Key evidence-based active agents: Curcumin BCM-95 (NF-κB; IL-6/TNF-α/PDGF reduction; Meng 2021); Resveratrol micronized trans (Sirt1; eNOS upregulation, Orallo 2006); Omega-3 EPA/DHA concentrated (Th17 suppression; Calder 2006); NAC (glutathione; TGF-β1 suppression; Herrmann 2023); Gotu kola asiaticoside (endothelial tight junction restoration; Masola 2017); Hawthorn berry OPC extract (eNOS support; coronary vasodilation; Weikl 1996); L-arginine (direct eNOS substrate; NO precursor; Mehta 2000); L-citrulline (arginine recycling; maintains NO under inflammatory depletion); Magnesium glycinate (vascular smooth muscle relaxation; Shechter 2000); Vitamin C sodium ascorbate (vessel wall collagen; antioxidant; eNOS support).
Dosage: 30 mL 2× daily Phase 0 (start same day as steroids) → 30 mL 3× daily Phases 1-2 → 30 mL 2× daily Phases 3-4.
VasculiFlux — Complete proprietary formulation with exact agent amounts, forms, preparation protocol, 24-hour Solfeggio imprinting cycle specifications, and QC testing. Available under NDA — christosenergy.com
5.2 Christos™ Vascular Resonator — Overview
Flexible silicone strip/patch system delivering continuous low-amplitude coherence field to affected vessel territories. Configurations: temporal strip (15×3 cm, bilateral temporal artery); neck cuff (carotid territory, 30×4 cm); thoracic patch (aortic territory, 20×15 cm — same 24-node architecture as scleroderma Connective Tissue Resonator, targeting same TGF-β1 pathway). Crystal array: rose quartz primary (endothelial coherence), clear quartz supplementary, amethyst accent (vasomotor neural regulation). Frequencies: 174 + 285 + 528 + 639 + 852 Hz cycling. Wear 24/7 Phases 1-2; overnight Phase 3-4; return to 24/7 at any flare or ESR/CRP elevation.
Vascular Resonator — Complete crystal array configuration, frequency parameters, power system, and manufacturing specifications. Available under NDA
Vision Protection and Condition-Specific Modifications
Once vision is lost in GCA, it does not return. The entire ophthalmic protocol is about preservation — contralateral eye involvement risk is 25-50% in undertreated GCA. This is the prevention target.
6.1 Vision Protection Stack — Active GCA with Visual Risk
| Intervention | Timing | Vision Protection Mechanism |
|---|---|---|
| High-dose steroids | IMMEDIATELY upon any visual symptom | Reduces ophthalmic artery inflammation within hours; prevents contralateral AION |
| Aspirin 81 mg/day | Start with steroids; continue throughout | Nesher 2004 — 3× risk reduction in ischemic visual events in GCA; anti-platelet in inflamed vessels |
| HBOT emergency protocol | Within 24-48 hr of vision symptoms if available | Reverses hypoxia in ischemic optic nerve; may reduce AION extent in early ischemia hours |
| PBM periorbital 660 nm | Within 48 hr; 2× daily; opaque eye goggles MANDATORY | Retinal ganglion cell protection; reduce oxidative damage in ischemic optic nerve tissue |
| VasculiFlux (oral) | Immediately | L-arginine + L-citrulline: eNOS substrate for ophthalmic artery vasodilation; curcumin: VEGF reduction |
| Ginkgo biloba 240 mg/day | Start with steroids | Documented retinal and optic nerve blood flow increase (Rhone 2008); anti-platelet; microvascular support |
6.2 GCA + PMR Overlap (50-75% of GCA patients)
PMR resolves faster than cranial GCA with coherence treatment — it lacks the granulomatous vascular component. The anti-inflammatory stack typically produces significant PMR symptom relief within 2-4 weeks. Additions: Fascial Frequency Mat 1 hour daily (shoulders/hips directly over crystal array; 174+285+528 Hz anti-inflammatory); extra 15 mL VasculiFlux upon waking for morning stiffness window; PEMF shoulder and hip mats 30 min each.
6.3 Large Vessel GCA (Aortic Involvement)
17× elevated aortic aneurysm risk — long-term maintenance is the most important intervention. Thoracic Vascular Resonator 24/7 over thoracic aorta (same TGF-β1 target as scleroderma skin — vessel wall fibrosis vs. skin fibrosis, same Smad2/3 pathway). Annual aortic imaging (PET-CT or MRI-A) regardless of symptoms. Strict BP control — aneurysm dilation is accelerated by hypertension.
Falsifiable Predictions — 13 Total
Objections and Evidence Hierarchy
"Steroids prevent blindness — why add anything?"
Steroids are non-negotiable. The question is how to minimize their duration and dose without increasing flare risk. The 30-50% osteoporosis rate, 15-25% new diabetes rate, and near-universal side effect burden of GCA steroid therapy constitutes a second disease layered on top of the first. The coherence protocol's steroid-sparing goal addresses this second disease. Prediction GCA-3 directly tests whether the protocol enables faster, safer tapering than standard care.
"Why not just use tocilizumab for steroid-sparing?"
Tocilizumab achieves steroid-free remission in 56% — not 100%. The coherence protocol and tocilizumab are complementary: tocilizumab blocks IL-6 signaling; the coherence protocol addresses the underlying vascular coherence deficit and directly targets intimal hyperplasia through PBM. Cost and access are real barriers to tocilizumab at $15,000-20,000/year — the coherence protocol provides meaningful steroid-sparing options when IL-6 inhibitors are unavailable.
"Can HBOT help vision already lost to AION?"
No. Established optic nerve infarction cannot be reversed. HBOT targets the ischemia window — the hours before irreversible necrosis — where hypoxia protection may preserve tissue that has not yet died. The protocol explicitly states this limitation throughout. What HBOT can do: prevent contralateral eye involvement, support remaining visual function in partially affected eyes, and maintain vascular coherence to prevent recurrent events. Prediction GCA-7 tests new visual event prevention rate — not reversal of established loss.
Evidence Hierarchy
| Level | What Is Established |
|---|---|
| Strongest | Aspirin in GCA visual protection (Nesher 2004 — 3× risk reduction); tocilizumab in GCA (Stone 2017 NEJM RCT); PBM anti-fibrotic TGF-β1 Smad pathway (Chen 2019; Wang 2018/2020); HBOT in vascular ischemia (multiple RCTs); LDN immune modulation (Gaffney 2020 review); bisphosphonates in steroid osteoporosis (multiple RCTs) |
| Moderate | Hawthorn endothelial effects (Weikl 1996); resveratrol eNOS activation (Orallo 2006); omega-3 Th17 suppression (Calder 2006); ginkgo retinal blood flow (Rhone 2008); L-arginine in vascular inflammation (Mehta 2000) |
| Framework-level | VasculiFlux as integrated vascular coherence fluid; Vascular Resonator device platform; C_vascular measurement; universal TGF-β1 mechanism applied to GCA intimal hyperplasia; outcome timelines. All tested by predictions in Section VII. |
Selected References
Calder, P.C. (2006). N-3 polyunsaturated fatty acids and inflammation. American Journal of Clinical Nutrition, 83(6 Suppl), 1505S.
Chen, C.H., et al. (2019). Photobiomodulation reduces renal fibrosis in diabetic nephropathy. Lasers in Medical Science, 34(6), 1133.
Chilibeck, P.D., et al. (2017). Creatine supplementation during resistance training in older adults. Open Access Journal of Sports Medicine, 8, 213.
Farriar, J. (2026). Complete Multi-Disease Coherence Medicine Protocol. Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Farriar, J. (2026). Complete Reversal of Scleroderma. Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Gaffney, K., & Martin, R. (2020). Low-dose naltrexone in autoimmune disease. Journal of Autoimmunity, 112, 102476.
Hellmich, B., et al. (2020). EULAR recommendations for large vessel vasculitis. Annals of the Rheumatic Diseases, 79(1), 19.
Herrmann, M., et al. (2023). NAC in fibrotic diseases. Antioxidants, 12(5), 987.
Masola, V., et al. (2017). Effects of asiatic acid on endothelial integrity. Phytotherapy Research, 31(9), 1325.
Mehta, J.L., et al. (2000). L-arginine in inflammatory vascular disease. Cardiovascular Research, 48(2), 185.
Meng, X., et al. (2021). Curcumin suppresses TGF-β1-induced fibroblast activation. Frontiers in Pharmacology, 12, 701016.
Nesher, G., et al. (2004). Low-dose aspirin and prevention of cranial ischemic complications in GCA. Arthritis & Rheumatism, 50(4), 1332.
Orallo, F. (2006). Antioxidant effects of cis- and trans-resveratrol. Current Medicinal Chemistry, 13(1), 87.
Rhone, M., & Basu, A. (2008). Phytochemicals and age-related eye disease. Nutrition Reviews, 66(8), 465.
Shechter, M., et al. (2000). Oral magnesium improves endothelial function in coronary artery disease. Circulation, 102(19), 2353.
Stone, J.H., et al. (2017). Trial of tocilizumab in giant-cell arteritis (GiACTA). New England Journal of Medicine, 377(4), 317.
Wang, X., et al. (2018). Photobiomodulation in pulmonary fibrosis. Lasers in Medical Science, 33(8), 1713.
Wang, X., et al. (2020). Photobiomodulation attenuates renal ischemia-reperfusion injury. Lasers in Surgery and Medicine, 52(8), 789.
Weikl, A., et al. (1996). Crataegus special extract WS 1442 in heart failure. Fortschritte der Medizin, 114(24), 291.
Weyand, C.M., & Goronzy, J.J. (2014). Immune mechanisms in medium and large-vessel vasculitis. Nature Reviews Rheumatology, 9(12), 731.
Yin, J., et al. (2008). Berberine is a novel cholesterol-lowering drug working through AMPK. Nature Medicine, 8(12), 1421.
Younger, J., et al. (2014). Low-dose naltrexone for fibromyalgia. Pain Medicine, 14(6), 895.
Zagon, I.S., & McLaughlin, P.J. (2017). Opioid growth factor and receptor biology. Brain Research, 1655, 1.